NovaBridge Biosciences - ADR opened higher at $0.89, compared with its previous close of $0.86. In the last trading session, the stock traded between $0.82 and $0.90. It showed a downward intraday trend.
An investment of $100 made 2 years ago in NovaBridge Biosciences - ADR is now worth
$ 18.24
Resulting in a loss of
$ 81.76 (81.76%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.03 (-3.60%)
Day High
$0.90
Day Low
$0.82
Day Open
$0.89
Prev Close
$0.86
Volume
6,92,604
1W Return
-18.15%
1M Return
-37.36%
3M Return
-54.72%
6M Return
-60.48%
1Y Return
-80.38%
Market Cap ($ Mn)
96
PE Ratio
-
PB Ratio
1.07
PEG Ratio
-
ROE
-40.67%
ROCE
-43.63%
EPS (TTM)
-
1 Week
-18.15%
1 Month
-37.36%
3 Months
-54.72%
6 Months
-60.48%
9 Months
-75.52%
Visara enters option agreement to acquire YOL104-2 rights
Visara, a subsidiary of NovaBridge Biosciences, signed an asset purchase option agreement with YOLO Immune. The deal provides an exclusive option to acquire worldwide rights to the YOL104 Program. Visara will develop and commercialize YOL104-2 for ocular surface squamous neoplasia (OSSN). YOLO Immune will receive an upfront payment, exercise fees, milestones, and royalties upon completion.
23 days agoNovaBridge to present givastomig combo data at ESMO Congress 2026
NovaBridge Biosciences will present updated Phase 1b data for givastomig at ESMO Congress 2026. The study evaluates givastomig combined with nivolumab and mFOLFOX6 in first-line metastatic gastroesophageal adenocarcinoma. FDA has granted Fast Track Designation to givastomig for this indication. Presentation scheduled for October 25, 2026, in Madrid, Spain.
1mo agoNovaBridge Biosciences H1FY26 Update: $216m cash, Phase 3 plans
NovaBridge holds $216 million in cash and investments, maintaining a debt-free balance sheet. Gvostomig received FDA Fast Track designation; Phase 3 study targeted for Q4 2026 initiation. VIS101 advances to Phase 2b study in H2 2026 following positive Phase 2a results. Financial runway extends through 2028, covering key oncology and ophthalmology milestones. Company explores European partnerships and women's health opportunities via business development.
1mo agoNovaBridge Biosciences to present at Cantor and Wainwright conferences
NovaBridge Biosciences leadership to present at two September 2026 investor conferences. CEO Srishti Gupta to lead fireside chats at Cantor and H.C. Wainwright events. Webcasts of sessions will be accessible on the company website for 90 days. Company portfolio includes oncology and ophthalmology programs givastomig and VIS-101.
2mo agoNovaBridge Biosciences H1FY26 net loss widens to $37.9 million
NovaBridge Biosciences reported a H1FY26 net loss of $37.9 million, widening from $8.7 million in the prior year, with an EPS miss of 135.71%. The company highlighted strategic progress, including the appointment of Srishti Gupta as CEO and advancements in its givastomig and VIS-101 pipelines, while maintaining $215.9 million in cash.
2mo agoNovaBridge Biosciences to report H1FY26 results on Aug 20
NovaBridge Biosciences will report its first-half 2026 financial results and provide a corporate update via webcast on August 20, 2026. The biotechnology firm, focused on oncology and ophthalmology programs including givastomig and VIS-101, will discuss its progress during the session scheduled for 9:00 am ET.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 2 years ago in NovaBridge Biosciences - ADR is now worth
$ 18.24
Resulting in a loss of
$ 81.76 (81.76%)
Note: Past profits do not guarantee future returns.
